Shield Therapeutics plc announced the exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd. for the development and commercialisation of Feraccru®/Accrufer® in China. The deal includes the $11.4 million upfront payment to Shield Therapeutics plc, up to $51.4 million in development and sales milestones, ongoing tiered double-digit royalties on net sales payable to Shield Therapeutics plc and ASK Pharm to be responsible for, and cover costs of, all development and regulatory activity.